The new rules, which are introduced by the Medicines and Healthcare Products Regulatory Agency (MHRA), enable the hospitals, ambulances, and even the local care settings in order to carry out the final stages when it comes to manufacturing highly customized treatments to offer specialized care to UK and to offer time-sensitive treatments by way of using regulated protocols.


It is well to be noted that until now, therapies like CAR-T, which involved modifying immune cells of the patient to fight their specific cancer, happened to be sent to specialist facilities, which were often located quite far. Delays went on to mean that some patients became too ill to receive the therapy, or the medicines having a short shelf life could not get delivered in time.
As per the new framework, a cancer patient can have their cells collected, altered, and even returned for treatment within days. Interestingly, a child with a rare genetic disorder could get freshly prepared therapy that is made and administered on-site, even if it only has a few minutes of shelf life left.
The new legislation goes on to apply to the cell and gene therapies and tissue-engineered treatments. Gases, blood products, medical gases, and 3-D printed products. Hospitals will follow protocols with oversight coming from a central control authority, which would be similar to how chemotherapy or antibiotics are getting prepared locally.
